The Pharmacy Times® Atopic Dermatitis Resource Center is a comprehensive resource for clinical news and expert insights on treatments for atopic dermatitis.
April 29th 2024
The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.